ReviewHematology. American Society of Hematology. Education Program2023
Inpatient recognition and management of HLH.
Review in Hematology. American Society of Hematology. Education Program, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 18 citations in OpenAlex.
- SevereClinical case reports · 2026Article
- Secondary hemophagocytic lymphohistiocytosis following bacterial pneumonia managed with dexamethasone monotherapy: a case report.Annals of medicine and surgery (2012) · 2026Article
- Machine learning of laboratory parameters to predict mortality risk in pediatric hemophagocytic lymphohistiocytosis: a retrospective single-center study.BMC pediatrics · 2026Article
- Early Risk Factors and Clinical Characteristics of Pediatric Hemophagocytic Lymphohistiocytosis: A Single-Center Retrospective Study.Journal of inflammation research · 2026Article
- Hemophagocytic Syndromes in Adults: Real-World Data on Mortality from a Tertiary Reference Center.Acta haematologica · 2026Article
- Influencing factors of peripheral blood indicators on 30-day mortality risk in children with hemophagocytic lymphohistiocytosis based on weighted quantile sum regression: a single-center retrospective cohort study.Frontiers in pediatrics · 2026Article
- Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis in the Gulf Cooperation Council: a modified Delphi approach.Frontiers in immunology · 2026Article
- Article
- Integration of Boruta algorithm and latent class analysis for risk factors of 30-day mortality in pediatric hemophagocytic lymphohistiocytosis based on peripheral blood indicators.Frontiers in pediatrics · 2026Article
- Article
- Hemophagocytic Lymphohistiocytosis in HIV/AIDS: Who Fired the First Shot, the Virus or Its Companions?Cureus · 2025Article
- The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in patients with lymphoma.Blood advances · 2025Article
- Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy.Hematology. American Society of Hematology. Education Program · 2024Review
- New Onset of Acute and Chronic Hepatic Diseases Post-COVID-19 Infection: A Systematic Review.Biomedicines · 2024Review
- Hemophagocytic Lymphohistiocytosis in Visceral Leishmaniasis: A Rare yet Treatable Complication.Cureus · 2024Article
- Hemophagocytic Lymphohistiocytosis Triggered by Herpes Simplex Virus 1 and 2: A Narrative Review.Hematology reports · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemophagocytic lymphohistiocytosis (HLH) is one of the life-threatening emergencies that a hematologist may be called upon to diagnose and manage. It is a hyperinflammatory process that develops in patients with genetic abnormalities, hematologic malignancies, chronic inflammatory states, or infections. The main clinical challenges are recognizing HLH, determining whether the immune response is aberrant or appropriate, and deciding upon therapy. Patients may present with fever, central nervous system symptoms, cytopenias, or elevated liver enzymes. Recognizing HLH is challenging because its features overlap with numerous systemic disorders, thus requiring a high level of suspicion and timely investigations to confirm the diagnosis and detect the underlying trigger. Once HLH is diagnosed, careful consideration of immunosuppressive therapy's potential benefit versus harm is necessary. Such therapy can sometimes be tailored to the underlying trigger. In the acute setting, the competing pressures of completing a thorough diagnostic process (including evaluation for the presence of lymphoma and infection) and the need for expedited treatment must be balanced. During the management of an HLH patient, continuous vigilance for the presence of as-yet unrecognized disease triggers, monitoring response, and identifying emerging complications is critical. This review will discuss the recognition and management of HLH in the inpatient setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.